The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients |
| |
| Authors: | Jong-Mu Sun Young-Woong Won Seung Tae Kim Jung Hoon Kim Yoon-La Choi Jeeyun Lee Yeon Hee Park Jin Seok Ahn Keunchil Park Myung-Ju Ahn |
| |
| Institution: | (1) Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul, 135-710, Korea;(2) Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
| |
| Abstract: | Background Epidermal growth factor receptor (EGFR) mutations are associated with sensitivity to gefitinib or erlotinib in non-small cell
lung cancer (NSCLC). We investigated the relationships between the two most common types of somatic EGFR mutations, exon 19
deletions and L858R mutations, and clinical outcomes of Korean NSCLC patients after treatment with gefitinib or erlotinib. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
